Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar 21;8(12):20510-20515.
doi: 10.18632/oncotarget.14724.

Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review

Peisi Kou  1   2 , Yan Zhang  2 , Wenbo Shao  3 , Hui Zhu  2 , Jingze Zhang  2 , Haiyong Wang  2 , Li Kong  2 , Jinming Yu  2   4   1
Affiliations
Review

Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review

Peisi Kou et al. Oncotarget. .

Abstract

Apatinib is a novel and highly selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2. Previous studies have suggested that apatinib is safe and effective in some solid tumors. We report one case with advanced hepatocellular carcinoma (HCC), who received apatinib combined with transhepatic arterial chemotherapy and embolization (TACE), and chemotherapy respectively. TACE was administered three times once a month, using lipiodol 10ml, oxaliplatin 150mg, and tegafur 1g. The dose of apatinib was 500 mg/d from day 4 to 24. After TACE, the patient received chemotherapy of regimen FOLFOX4, oxaliplatin intravenously at 85 mg/m2 on day 1, calcium levofolinate 200 mg/m2 on day 1 and 2, 5-fluorouracil 400 mg/m2 intravenously and 5-fluorouracil 600 mg/m2 intravenously pumped for 22h on day 1 and 2, cycled every two weeks for seven cycles. He took concurrently apatinib with a dose of 500mg daily from 1 to 10 days per cycle. He was confirmed as partial response (PR) by the Response Evaluation Criteria in Solid Tumors (RECIST). The level of serum alpha-fetoprotein (AFP) decreased from 60500 ng/ml to 12.7 ng/ml, and the progression free survival (PFS) time was more than eight months. It indicated that apatinib may be a superior choice for HCC patients.

Keywords: apatinib; hepatocellular carcinoma; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. Abdomen CT images show that one of the lesions is located in the top of liver
A. In the venous phase, the mass is low density and irregular. B. The arrow represents tumor thrombus in the left branch of portal vein.
Figure 1
Figure 1. Abdomen CT images show that one of the lesions is located in the top of liver
A. In the venous phase, the mass is low density and irregular. B. The arrow represents tumor thrombus in the left branch of portal vein.
Figure 2
Figure 2. Hematoxylin and eosin staining of a tumor section (×200)
The pathological diagnosis is HCC.
Figure 3
Figure 3. Tumor shrinkage was confirmed
CT scan on March 2016 A. and on May 2016 B. showed that tumor was smaller after using apatinib.
Figure 3
Figure 3. Tumor shrinkage was confirmed
CT scan on March 2016 A. and on May 2016 B. showed that tumor was smaller after using apatinib.
Figure 4
Figure 4. The level of serum AFP keeps falling during treatment
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32. - PubMed
    1. Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, Cheng Y, Wang Z, Zheng L, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol. 2013;31:3219–25. - PubMed
    1. Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, et al. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016;34:1448–54. - PubMed
    1. Qin S. Apatinib in Chinese patients with advanced hepatocellular carcinoma: A phase II randomized, open-label trial. Journal Of Clinical Oncology. 2014;32(Suppl 5) abstract 4019.
    1. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34. - PubMed

MeSH terms

Supplementary concepts